News

Filter

Current filters:

Jubilant

1 to 9 of 95965 results

Vifor reports positive results from Ferinject study for chronic heart failure

Vifor reports positive results from Ferinject study for chronic heart failure

01-09-2014

Switzerland-based iron specialist Vifor Pharma says its Ferinject (ferric carboxymaltose) has met its…

Cardio-vascularChronic heart failureFerinjectPharmaceuticalRegulationSwitzerlandVifor Pharma

Ablynx out-licenses ozoralizumab for Greater China to Eddingpharm

Ablynx out-licenses ozoralizumab for Greater China to Eddingpharm

01-09-2014

Belgian drug developer Ablynx has expanded its relationship with China’s Eddingpharm, by granting the…

AblynxAnti-Arthritics/RheumaticsChinaEddingpharmLicensingMarkets & MarketingozoralizumabPharmaceutical

Chugai and Roche amend business arrangements on out-licensing

Chugai and Roche amend business arrangements on out-licensing

31-08-2014

Japanese drugmaker Chugai has amended the business arrangements with its majority (62%) share-owner Swiss…

Asia-PacificChugai PharmaceuticalEuropeLicensingPharmaceuticalRoche

Novartis' investigational heart failure drug LCZ696 shows striking efficacy

Novartis' investigational heart failure drug LCZ696 shows striking efficacy

31-08-2014

Swiss drug major Novartis on Saturday presented striking new data for its LZC696 heart drug at the European…

Cardio-vascularLCZ696NovartisPharmaceuticalRegulationResearch

United Thera scores over Sandoz in Remodulin patent case

United Thera scores over Sandoz in Remodulin patent case

31-08-2014

US biotech company United Therapeutics’ shares leapt 28.5% to $117.83 on Friday, after the company…

GenericsLegalNovartisPatentsRemodulinRespiratory and PulmonarySandozUnited TherapeuticsUSA

Positive results from four pivotal alirocumab trials at ESC Congress

Positive results from four pivotal alirocumab trials at ESC Congress

31-08-2014

French pharma major Sanofi and US partner Regeneron Pharmaceuticals have announced detailed positive…

alirocumabBiotechnologyCardio-vascularRegeneron PharmaceuticalsResearchSanofi

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

31-08-2014

Japan’s largest drugmaker Takeda Pharmaceutical and US pharma major Eli Lilly have failed in their…

ActosDiabetesEli LillyFinancialLegalPharmaceuticalTakeda PharmaceuticalUSA

1 to 9 of 95965 results

Back to top